Olodaterol
Stiolto, Striverdi (olodaterol) is a small molecule pharmaceutical. Olodaterol was first approved as Striverdi respimat on 2014-07-31. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. The pharmaceutical is active against beta-2 adrenergic receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Striverdi
CombinationsStiolto
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| stiolto respimat | New Drug Application | 2020-10-20 |
| striverdi respimat | New Drug Application | 2020-09-29 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Olodaterol Hydrochloride, Striverdi Respimat, Boehringer Ingelheim | |||
| 8733341 | 2030-10-16 | DP | |
| 7837235 | 2028-03-13 | DP | |
| 9027967 | 2027-03-31 | DP | |
| 7727984 | 2027-01-19 | DP | |
| 7396341 | 2026-10-10 | DP | U-1547 |
| 7896264 | 2025-05-26 | DP | |
| 7220742 | 2025-05-12 | DS, DP | U-1547, U-1703 |
| 8034809 | 2025-05-12 | U-1547, U-1702 | |
| 7284474 | 2024-08-26 | DP | |
| 7056916 | 2023-12-07 | DS, DP | |
| 7491719 | 2023-11-10 | DS, DP | |
| 7786111 | 2023-11-10 | DP | |
| 8044046 | 2023-11-10 | U-1547, U-1702 | |
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AC: Selective beta-2-adrenoreceptor agonist inhalants
— R03AC19: Olodaterol
— R03AL: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
— R03AL06: Olodaterol and tiotropium bromide
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OLODATEROL |
| INN | olodaterol |
| Description | Olodaterol is a member of the class of benzoxazine that is 6-hydroxy-1,4-benzoxazin-3-one in which the hydrogen at position 4 is replaced by a (1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino}ethyl group. Used (as its hydrochloride salt) for long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease including chronic bronchitis and/or emphysema. It has a role as a beta-adrenergic agonist and a bronchodilator agent. It is a benzoxazine, a member of phenols, an aromatic ether, a secondary alcohol and a secondary amino compound. It is a conjugate base of an olodaterol(1+). |
| Classification | Small molecule |
| Drug class | bronchodilators (phenethylamine derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 868049-49-4 |
| RxCUI | 1546059 |
| ChEMBL ID | CHEMBL605846 |
| ChEBI ID | 82700 |
| PubChem CID | 11504295 |
| DrugBank | DB09080 |
| UNII ID | VD2YSN1AFD (ChemIDplus, GSRS) |
Target
Agency Approved
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 799 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
131,465 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more